Nanjing Pharmaceutical Group Co Ltd

Nanjing Pharmaceutical Group Co Ltd has a market price of 5.03 CNY per share, with a market capitalization of 6.58 billion CNY. The company's price-to-earnings ratio is 10.54, and its price-to-book ratio is 0.92, indicating that the market values the company slightly below its book value. The enterprise value to EBITDA ratio is 13.76, and the enterprise value to revenue ratio is 0.29, suggesting a relatively low valuation compared to its revenue. The company's profitability metrics show a return on equity of 8.7% and a return on assets of 1.99%. These figures are below the industry median for pharmaceutical companies, indicating that the company is not generating returns as efficiently as its peers. The gross profit margin is 6.12%, and the operating margin is 2.11%, both of which are below the industry median, further highlighting the company's underperformance in profitability. Nanjing Pharmaceutical Group Co Ltd's revenue is primarily concentrated in China, with no significant international exposure disclosed in the available data. The company's revenue concentration in a single geographic region increases its exposure to local economic and regulatory risks. The company's revenue for the latest period is 54.96 billion CNY, with a gross profit of 3.37 billion CNY and an operating income of 1.16 billion CNY. The company's growth trajectory is mixed. The latest revenue of 54.96 billion CNY is higher than the analyst estimate of 31.30 billion CNY, indicating strong performance in the most recent period. However, the company's free cash flow is 355.84 million CNY, and its operating cash flow is 91.81 million CNY, suggesting that the company is generating positive cash flow but at a relatively modest level. The capital expenditure is negative at -251.37 million CNY, indicating that the company is reducing its capital spending. The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of concern is that the company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The debt-to-equity ratio is 1.3, indicating a relatively high level of leverage. The current ratio of 1.53 suggests that the company has sufficient current assets to cover its current liabilities. Recent events and filings indicate that the company has not issued any new shares in the recent period, and there are no immediate plans for additional dilution. The company's financial performance and risk profile suggest that it is a stable but underperforming player in the pharmaceutical industry.